CLINICAL TRIALS PROFILE FOR HISTAMINE

505(b)(2) Clinical Trials for HISTAMINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00124787 ↗	A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis	Completed	Canadian Association of Emergency Physicians	Phase 4	2005-04-01	Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC	NCT00124787 ↗	A Trial Comparing the Effect of Oral Dimenhydrinate Versus Placebo in Children With Gastroenteritis	Completed	St. Justine's Hospital	Phase 4	2005-04-01	Dimenhydrinate, an over-the-counter, widely used drug in Canada, is an ethanolamine-derivative anti-histamine. It limits the stimulation of the vomiting center by the vestibular system, which is rich in histamine receptors. Multiple studies have shown its effectiveness in treatment of post-operative nausea and vomiting in children. It is also used for treatment of vertigo in children. Furthermore, it has the potential to be much more cost-effective than ondansetron, with an average cost of $0.90 US per dose . Its principal side effects are drowsiness, dizziness and anticholinergic symptoms. Restlessness and insomnia have also been described in children. To date, there has been no published data on the efficacy of dimenhydrinate in controlling emesis in children with acute gastroenteritis. RESEARCH QUESTION Do children treated with oral dimenhydrinate during acute gastro-enteritis experience less vomiting episodes than children treated with placebo?
OTC	NCT01537471 ↗	The Effects of Antihistamines on Pre-Pulse Inhibition	Completed	Wallace H. Coulter Foundation	Phase 1	2012-01-01	The purpose of the investigators research is to test whether problems people have with processing their senses (feeling overwhelmed, distracted or upset by sounds and other stimuli) can be lessened by meclizine, a drug found in many over the counter antihistamines, which are medicines used for things like allergies, sleep problems, or the common cold.
OTC	NCT01537471 ↗	The Effects of Antihistamines on Pre-Pulse Inhibition	Completed	Duke University	Phase 1	2012-01-01	The purpose of the investigators research is to test whether problems people have with processing their senses (feeling overwhelmed, distracted or upset by sounds and other stimuli) can be lessened by meclizine, a drug found in many over the counter antihistamines, which are medicines used for things like allergies, sleep problems, or the common cold.
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Dalhousie University	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Nova Scotia Health Authority	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Lisa Barrett	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.

All Clinical Trials for HISTAMINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003991 ↗	Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia	Completed	Maxim Pharmaceuticals	Phase 3	1998-07-01	RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission. PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.
NCT00004316 ↗	Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis	Completed	University of Pittsburgh	Phase 1/Phase 2	1995-06-01	OBJECTIVES: I. Estimate the optimal safe dose of intravesical capsaicin in patients with interstitial cystitis. II. Evaluate the efficacy of 0.025% topical capsaicin in relieving chronic burning pain in patients with vulvar vestibulitis. III. Evaluate the effect of capsaicin on type C nerve fibers in bladder mucosa and vulvar skin. IV. Evaluate the effect of C fiber depletion on urinary levels of histamine and prostaglandin.
NCT00004316 ↗	Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1/Phase 2	1995-06-01	OBJECTIVES: I. Estimate the optimal safe dose of intravesical capsaicin in patients with interstitial cystitis. II. Evaluate the efficacy of 0.025% topical capsaicin in relieving chronic burning pain in patients with vulvar vestibulitis. III. Evaluate the effect of capsaicin on type C nerve fibers in bladder mucosa and vulvar skin. IV. Evaluate the effect of C fiber depletion on urinary levels of histamine and prostaglandin.
NCT00005038 ↗	Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer	Unknown status	The Christie NHS Foundation Trust	Phase 2	1999-06-01	RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. Histamine dihydrochloride may prolong survival and improve quality of life in patients with metastatic kidney cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have metastatic kidney cancer.
NCT00029679 ↗	Borage Oil and Ginkgo Biloba (EGb 761) in Asthma	Completed	National Center for Complementary and Integrative Health (NCCIH)	Phase 1/Phase 2	2000-09-01	This study will assess clinical efficacy and/or adverse effects of dietary borage oil (which contains gamma-linolenic acid [GLA]) and Ginkgo biloba in patients with mild persistent to moderate asthma.
NCT00039234 ↗	Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver	Unknown status	National Cancer Institute (NCI)	Phase 3	2002-09-01	RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known if interleukin-2 is more effective with or without histamine dihydrochloride in treating stage IV melanoma that is metastatic to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have stage IV melanoma that is metastatic to the liver.
NCT00039234 ↗	Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver	Unknown status	Maxim Pharmaceuticals	Phase 3	2002-09-01	RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug. It is not yet known if interleukin-2 is more effective with or without histamine dihydrochloride in treating stage IV melanoma that is metastatic to the liver. PURPOSE: Randomized phase III trial to compare the effectiveness of interleukin-2 with or without histamine dihydrochloride in treating patients who have stage IV melanoma that is metastatic to the liver.

Clinical Trial Conditions for HISTAMINE

Condition Name

Condition Name for HISTAMINE
Intervention	Trials
Asthma	22
Allergic Rhinitis	17
Pruritus	8
Itch	8

Condition MeSH

Condition MeSH for HISTAMINE
Intervention	Trials
Rhinitis	30
Rhinitis, Allergic	28
Asthma	18
Pruritus	14

Clinical Trial Locations for HISTAMINE

Trials by Country

Trials by Country for HISTAMINE
Location	Trials
United States	210
Canada	32
United Kingdom	22
Belgium	19
Germany	17

Trials by US State

Trials by US State for HISTAMINE
Location	Trials
New York	21
Illinois	13
Texas	13
North Carolina	12
Florida	11

Clinical Trial Progress for HISTAMINE

Clinical Trial Phase

Clinical Trial Phase for HISTAMINE
Clinical Trial Phase	Trials
PHASE4	8
PHASE3	1
PHASE2	7

Clinical Trial Status

Clinical Trial Status for HISTAMINE
Clinical Trial Phase	Trials
Completed	169
Recruiting	49
Unknown status	25

Clinical Trial Sponsors for HISTAMINE

Sponsor Name

Sponsor Name for HISTAMINE
Sponsor	Trials
Aalborg University	11
GlaxoSmithKline	11
Charite University, Berlin, Germany	5

Sponsor Type

Sponsor Type for HISTAMINE
Sponsor	Trials
Other	319
Industry	110
NIH	23

Histamine Clinical Trials, Market Analysis, Forecast, and Regulatory Status

Last updated: August 1, 2026

Histamine is not a conventional standalone prescription drug in major pharmaceutical markets. The clinically relevant product is histamine dihydrochloride, marketed in Europe as Ceplene in combination with interleukin-2 for adult patients with acute myeloid leukemia in first complete remission. The product has limited commercial scope, no established U.S. approval, no broad generic market, and no transparent standalone revenue base. Its commercial outlook depends on niche oncology use, regulatory reactivation, and evidence supporting immune-modulating combinations.

What is histamine dihydrochloride used for?

Histamine dihydrochloride is an immunomodulatory agent that inhibits myeloid-derived suppressor cells and supports T-cell and natural-killer-cell activity under specific treatment conditions. Its principal pharmaceutical use has been combination treatment with low-dose interleukin-2 in AML maintenance therapy.

Ceplene received European marketing authorization in 2008 for adult patients with AML in first remission who were unable to undergo autologous stem-cell transplantation or had no suitable donor. The treatment was designed to reduce relapse risk after remission induction and consolidation therapy. The authorization was based on clinical data showing benefit in selected AML populations, particularly patients with low residual disease burden.

The product is not a broad histamine-receptor agonist therapy. Its clinical rationale differs from antihistamines, H1 blockers, H2 blockers, and newer histamine-pathway oncology programs.

Item	Histamine dihydrochloride
Active ingredient	Histamine dihydrochloride
Key product	Ceplene
Original developer	Swedish Orphan Biovitrum and predecessor entities
Combination partner	Interleukin-2
Main indication	AML maintenance after first remission
U.S. FDA approval	No established approval
European regulatory status	Historically authorized; commercial and authorization status has changed over time
Administration	Subcutaneous injection
Therapeutic category	Immunomodulatory oncology agent
Primary commercial risk	Narrow indication and limited treatment adoption

What clinical trials have evaluated histamine?

Clinical development has focused on AML, solid tumors, and immune modulation. The strongest clinical rationale has been in AML, where histamine dihydrochloride is intended to protect immune effector cells from oxidative suppression by malignant myeloid cells.

AML clinical development

The central development program evaluated histamine dihydrochloride plus low-dose interleukin-2 as post-remission therapy. The treatment was administered after patients achieved complete remission and was intended to reduce relapse through immune surveillance.

A European randomized study reported improved leukemia-free survival in selected AML patients receiving histamine dihydrochloride plus interleukin-2 compared with observation or control treatment. The results were most relevant to patients with low or intermediate relapse risk and minimal residual disease levels that permitted immune-mediated control. The clinical effect was less compelling in patients with high residual disease burden.

The regimen has practical limitations:

• Repeated subcutaneous administration.
• Multi-week treatment cycles.
• Interleukin-2-related toxicity and administration burden.
• Need for treatment after remission rather than during active disease.
• Competition from allogeneic transplantation, targeted agents, oral maintenance drugs, and measurable-residual-disease-directed approaches.

Solid-tumor and immune-oncology trials

Histamine-based regimens have been evaluated in melanoma, renal cell carcinoma, pancreatic cancer, colorectal cancer, and other malignancies. These studies generally examined histamine dihydrochloride as an immune-modulating component with cytokines, vaccines, chemotherapy, or other immunotherapies.

The solid-tumor development record has not produced a broad commercial indication. Results have been inconsistent, and histamine has competed with checkpoint inhibitors, cellular therapies, antibody-drug conjugates, and targeted agents that have stronger regulatory and commercial positioning.

Trial status and evidence quality

Public clinical-trial records contain studies using histamine or histamine dihydrochloride as an intervention, but the program is fragmented across discontinued, completed, and investigator-sponsored studies. The commercial relevance of a trial depends on whether it supports a registration strategy, a new indication, or combination use with an approved oncology product.

Development area	Clinical rationale	Commercial assessment
AML post-remission maintenance	Immune restoration after remission	Strongest historical use case
AML with interleukin-2	Combination immune therapy	Limited by administration burden and changing AML standards
Melanoma	Immune activation and myeloid-cell suppression	Superseded by checkpoint inhibitors
Renal cell carcinoma	Immune modulation	Limited differentiation
Pancreatic cancer	Reduction of immunosuppressive myeloid signaling	High unmet need but difficult clinical setting
Vaccine combinations	Improved immune response	Early-stage and commercially uncertain

What is the FDA regulatory status of histamine?

Histamine dihydrochloride does not have a broadly established FDA-approved product comparable to approved AML therapies such as azacitidine, decitabine, oral azacitidine, or targeted drugs for FLT3-, IDH1-, IDH2-, or BCL2-dependent disease.

The U.S. development pathway would require a sponsor to establish:

1. A clinically meaningful AML indication.
2. A reproducible dosing regimen.
3. An acceptable safety profile for post-remission patients.
4. A manufacturing and quality package for the injectable product.
5. Evidence that the regimen improves relapse-free or overall survival over current standards.
6. A commercial rationale in a treatment market with multiple established maintenance and transplant options.

No widely recognized U.S. Orange Book listing creates a conventional generic-entry framework for histamine dihydrochloride. Any future U.S. sponsor would likely face regulatory work comparable to a new oncology biologic-combination or repurposed-drug program rather than a simple generic launch.

What is the European regulatory status of Ceplene?

Ceplene received a European Union authorization for AML maintenance in combination with interleukin-2. The product’s commercial trajectory has been constrained by narrow eligibility criteria, specialist use, and competition from transplant and newer AML therapies.

The European approval did not create a large international market because the product was not broadly adopted across all AML patients. Its clinical value was concentrated in patients who had achieved remission and lacked a practical transplant option.

Regulatory status should be assessed separately by country because national reimbursement, commercial availability, and authorization status can diverge from the original European authorization. European market access also depends on whether the product is actively supplied, reimbursed, or supported by a current marketing authorization holder.

What patents protect histamine dihydrochloride?

The historical intellectual-property position for histamine dihydrochloride was likely concentrated in formulation, dosing, combination, and method-of-use claims rather than composition-of-matter protection. Histamine is an established endogenous molecule, which limits the ability to obtain a strong new-molecule patent estate.

Potential protection categories include:

Patent category	Potential subject matter	Strategic value
Combination therapy	Histamine dihydrochloride with interleukin-2	Historically central to AML use
Method of treatment	Post-remission AML maintenance	Depends on claim scope and expiry
Patient selection	Minimal residual disease or relapse-risk subgroup	Can improve differentiation
Dosing schedule	Sequential or cyclical administration	Usually vulnerable to design-around
Formulation	Injectable histamine composition	May protect product handling or stability
Manufacturing	Purification, concentration, or sterile production	Relevant to supply barriers
Delivery	Subcutaneous administration protocols	Generally narrower than composition claims

The absence of a strong composition-of-matter barrier means that long-term exclusivity would depend on surviving method-of-use claims, regulatory exclusivity, trade secrets, manufacturing know-how, and commercial execution. No major, current Paragraph IV litigation campaign or established U.S. generic-entry dispute is publicly associated with Ceplene.

When does histamine lose exclusivity?

There is no single global exclusivity date for histamine. The relevant dates depend on the specific patent, jurisdiction, claim type, and regulatory authorization.

For a mature histamine-dihydrochloride product, the principal exclusivity barriers are likely to be limited or expired, particularly for the active ingredient itself. Any remaining protection would more likely relate to:

• Combination use with interleukin-2.
• Specific AML patient populations.
• Treatment sequencing.
• Formulation and stability.
• Manufacturing processes.
• Country-specific regulatory rights.

Because histamine dihydrochloride is an old and well-characterized compound, a new sponsor would not normally rely on basic molecule exclusivity. A reformulated or newly positioned product could obtain patents only for genuinely novel technical features.

Are there Paragraph IV challenges or generic launch risks?

The generic risk is unusual because the U.S. market lacks a clearly established reference product with broad commercial penetration. A conventional abbreviated new drug application could be difficult if the proposed product relies on the same combination regimen, method of use, and clinical labeling as the European product but lacks a U.S. reference drug.

The main competitive risks are therefore not conventional Paragraph IV challenges. They are:

• Off-label use of compounded or hospital-sourced histamine products.
• Substitution by approved AML maintenance therapies.
• Use of oral agents that reduce administration burden.
• Transplant referral for eligible patients.
• Clinical-trial enrollment in newer immune or targeted therapies.
• Reimbursement resistance for a combination with limited contemporary evidence.

A generic manufacturer could pursue a product if a regulatory pathway and reference listing became available. The commercial case would remain weak without a sizeable reimbursed indication.

How strong is the histamine patent estate?

The patent estate is weak to moderate from a long-term pharmaceutical perspective.

The strength is limited by the age of histamine, the availability of prior art, the dependence on combination and method claims, and the narrow AML population. Method-of-use patents can still create meaningful barriers if they cover a specific patient subgroup and dosing regimen, but their value declines as clinical practice changes.

The strongest potential protection would cover a technically defined combination that produces a clinically demonstrated outcome, such as relapse reduction in a biomarker-selected AML population. Broad claims covering histamine as an immune stimulant would face substantial validity and enablement pressure.

How does histamine compare with competing AML maintenance therapies?

Histamine dihydrochloride occupies a narrow position in AML. It is a post-remission immune-maintenance product rather than a frontline cytotoxic, targeted therapy, or transplant substitute.

Therapy category	Representative products	Relative position versus histamine
Oral hypomethylating maintenance	Oral azacitidine	More convenient and commercially established
BCL2-directed therapy	Venetoclax combinations	Stronger active-disease positioning
FLT3-targeted therapy	Midostaurin, quizartinib, gilteritinib	Biomarker-defined and more integrated into AML treatment
IDH-targeted therapy	Ivosidenib, enasidenib	Genotype-specific differentiation
Allogeneic transplant	Donor-based cellular therapy	Potentially curative but limited by eligibility and toxicity
Histamine plus interleukin-2	Ceplene regimen	Narrow post-remission immune-maintenance role

Histamine’s main advantage is a distinct immune mechanism and a potentially manageable safety profile in selected patients. Its disadvantages are weaker contemporary differentiation, injection burden, combination dependence, and limited regulatory reach.

What is the market size and revenue outlook for histamine?

No reliable public market estimate supports a large standalone histamine-drug market. Histamine is sold in multiple non-oncology contexts as a laboratory reagent, diagnostic material, or pharmacologic tool, but those categories should not be combined with prescription oncology revenue.

The commercial market for histamine dihydrochloride in AML is structurally small. A realistic forecast must use treated-patient assumptions rather than a broad global histamine market figure.

Base-case market outlook

The base case is a niche or inactive oncology market unless a sponsor secures new regulatory approval and demonstrates superiority or meaningful differentiation against existing AML maintenance options.

Scenario	Market condition	Five-year commercial outlook
Downside	No new sponsor, no regulatory reactivation	Minimal prescription revenue
Base case	Restricted European availability and limited specialist use	Low, geographically concentrated revenue
Upside	New AML approval with biomarker-selected use	Moderate niche revenue
High upside	Positive combination data in AML or another major cancer	Larger oncology opportunity, but low probability

Revenue would depend on the number of AML patients in first remission who are transplant-ineligible, have suitable residual-disease characteristics, and can tolerate interleukin-2. Even with regulatory approval, the addressable population would be much smaller than the total AML market.

Which companies are developing histamine-based therapies?

The principal commercial history is associated with Ceplene and predecessor organizations, including Swedish Orphan Biovitrum-related operations. Histamine has also appeared in academic and investigator-sponsored oncology research.

The field has not developed into a crowded commercial class. There is no established competitive group comparable to the PD-1, BTK, PARP, or BCL2 inhibitor markets. Current competition comes mainly from alternative AML treatment platforms rather than from other histamine products.

Potential licensing value would center on:

• Rights to historical clinical and regulatory data.
• European marketing rights.
• Manufacturing and sterile-injection capabilities.
• Combination rights with interleukin-2 or newer immune agents.
• Biomarker and minimal-residual-disease development.

What manufacturing and intellectual-property barriers exist?

Histamine dihydrochloride is chemically simple compared with biologics and complex small molecules. Manufacturing barriers are therefore more likely to involve sterile injectable production, impurity control, stability, packaging, and validated delivery systems.

The combination regimen creates operational complexity because histamine is used with interleukin-2 under a defined treatment schedule. A commercial sponsor would need reliable supply of both products, clear administration protocols, and reimbursement for the combined treatment.

Trade-secret protection could matter in:

• Sterile manufacturing.
• Product stability.
• Container-closure systems.
• Injection-site tolerability.
• Batch consistency.
• Storage and distribution.

These barriers can delay competitors but rarely provide the same protection as a valid composition-of-matter patent.

What generic launch scenarios exist?

Three launch scenarios are plausible.

European niche launch

A sponsor could reintroduce histamine dihydrochloride in selected European markets through a specialty-oncology strategy. This would require active authorization, national reimbursement, specialist education, and supply continuity.

U.S. repurposing program

A sponsor could pursue a U.S. AML indication using historical data supplemented by a modern controlled trial. The investment would be substantial because the product lacks broad FDA commercial infrastructure and would face competing standards of care.

Reformulated or biomarker-selected product

A new formulation or a patient-selected regimen could support new patent filings and clinical differentiation. The most defensible strategy would focus on measurable residual disease, immune biomarkers, or a modern combination partner rather than the historical broad AML population.

Key Takeaways

• Histamine’s pharmaceutical relevance is concentrated in histamine dihydrochloride, particularly the former Ceplene AML regimen.
• The strongest clinical evidence is in post-remission AML maintenance combined with interleukin-2.
• Histamine has no established broad U.S. FDA market or conventional Orange Book generic pathway.
• Its historical European authorization created a niche product, not a large oncology franchise.
• The active ingredient is old, so long-term exclusivity depends on method-of-use, combination, formulation, and manufacturing claims.
• No major current Paragraph IV litigation or generic challenge defines the market.
• Commercial competition comes from oral azacitidine, targeted AML therapies, venetoclax-based regimens, and allogeneic transplantation.
• The base-case market is small unless new clinical data support biomarker-selected AML use or a new immune-oncology combination.
• The most credible upside strategy is a modern, evidence-driven AML program with measurable-residual-disease selection and a differentiated dosing or formulation platform.

FAQs About Histamine Drug Development and Commercialization

Is histamine dihydrochloride approved by the FDA?

Histamine dihydrochloride does not have a broadly established FDA-approved oncology product comparable to approved AML maintenance therapies.

Is Ceplene still commercially available?

Ceplene’s availability depends on jurisdiction, marketing authorization status, national reimbursement, and active commercial supply. Its historical European authorization does not guarantee current availability in every European market.

Can histamine dihydrochloride be developed as a generic?

A generic pathway would depend on the existence of an approved reference product, regulatory listing, pharmaceutical equivalence, and applicable method-of-use requirements. The lack of a broad U.S. reference market complicates a conventional generic strategy.

Does histamine have potential in immunotherapy combinations?

Yes, but the clinical opportunity depends on showing that histamine improves outcomes with a modern immune or targeted therapy. Historical results alone are unlikely to support a large commercial program.

What is the primary investment risk for histamine-based oncology drugs?

The primary risk is limited clinical and commercial differentiation against established AML maintenance therapies, combined with a narrow eligible patient population and uncertain regulatory infrastructure.

References

1. European Medicines Agency. (2008). Ceplene: EPAR - Product information. European Medicines Agency.

2. Brune, M., Castaigne, S., Catalano, J., Gehlsen, K., Ho, A. D., Hofmann, W. K., Hogge, D. E., Nilsson, B., Or, R., Romero, P., et al. (2006). Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: Results of a randomized phase 3 trial. Blood, 108(1), 88-96.

3. National Cancer Institute. (n.d.). Histamine dihydrochloride. NCI Drug Dictionary.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book. U.S. Department of Health and Human Services.

5. European Medicines Agency. (n.d.). Medicines for human use and European public assessment reports. European Medicines Agency.

6. National Library of Medicine. (n.d.). ClinicalTrials.gov search results for histamine dihydrochloride and histamine oncology studies. U.S. National Library of Medicine.